Turning new ideas into molecules that positively impact human health

Our pipeline

Target
(Disease) Disease
Discovery
Preclinical
Clinical

FXR

Agonists

Licensed to Intercept Pharmaceuticals

Metabolic

ACMSD

Inhibitors

Metabolic

NR2F6

Antagonists

Cancer

LRH-1

Inverse agonists

Partnered with Sterling

Cancer
News View all

“Farmaci, i Successi del Made in Italy” Tes Pharma in "Otto e Mezzo" of La7

Dec 2, 2022

POR FESR 2014-2020, Asse I, Azione 3.4.1. – Avviso Large 2021 – Regione Umbria

Feb 21, 2023

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

Nov 8, 2022

X-ray Structure of Human ACMSD with TES-1025

Apr 8, 2022

Prof. Roberto Pellicciari Recipient of the EFMC Honorary Fellow Award.

Aug 18, 2021

POR FESR 2014-2020, Asse I, Azione 1.1.1. – Avviso Ricerca 2020 – Regione Umbria

Jul 15, 2021
Careers

We are always looking for talent and passion.

Find out if we have open positions.
Contacts

Don’t be shy!
Say Hi!

Send us an email.